Experimental groups were intraperitoneally injected with three doses of anti-Programmed cell death 1 (PD-1) in 3-day intervals for 17 days, and they experienced a significant tumor size reduction and improved survival compared to the control group. Here, PDCD1 is linked to neoplasm.